Chemical compound
Pharmaceutical compound
Figitumumab (previously CP-751871) is a monoclonal antibody [ 1] insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer , for example adrenocortical carcinoma [ 2] non-small cell lung cancer (NSCLC).[ 3]
This drug was being developed by Pfizer , but they ceased development of the drug in January 2011 and has stopped its manufacture.[ 4]
Anti-cancer mechanism
See Insulin-like growth factor 1 receptor role in cancer .
Clinical trials
The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths[ 5] [ 6] [ 7]
It was to have been included in the I-SPY2 breast cancer trial.[ 8]
References
^ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab , American Medical Association .^ Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. (March 2010). "Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma" . Cancer Chemotherapy and Pharmacology . 65 (4): 765–73. doi :10.1007/s00280-009-1083-9 . PMC 2875253 PMID 19649631 . ^ Gualberto A, Karp DD (July 2009). "Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer". Clinical Lung Cancer . 10 (4): 273–80. doi :10.3816/CLC.2009.n.038 . PMID 19632947 . ^ "Cancer sufferer fears future without 'life-saver' drug" . BBC News . July 2014.^ Krauskopf L (29 December 2009). "Pfizer ends late-stage lung-cancer study" . Reuters. ^ Clinical trial number NCT00976508 ClinicalTrials.gov
^ Clinical trial number NCT00635245 ClinicalTrials.gov
^ "Breast cancer study aims to speed drugs, cooperation" . Reuters. March 2010.
Angiopoietin CNTF EGF (ErbB)
FGF
FGFR1 FGFR2
Agonists: Ersofermin FGF (1 , 2 (bFGF) , 3 , 4 , 5 , 6 , 7 (KGF ), 8 , 9 , 10 (KGF2) , 17 , 18 , 22 )Palifermin Repifermin Selpercatinib Sprifermin Trafermin FGFR3 FGFR4 Unsorted
HGF (c-Met) IGF
LNGF (p75NTR ) PDGF RET (GFL)
SCF (c-Kit) TGFβ Trk
TrkA
Negative allosteric modulators: VM-902A TrkB
Agonists: 3,7-DHF 3,7,8,2'-THF 4'-DMA-7,8-DHF 7,3'-DHF 7,8-DHF 7,8,2'-THF 7,8,3'-THF Amitriptyline BDNF BNN-20 Deoxygedunin Deprenyl Diosmetin DMAQ-B1 HIOC LM22A-4 N-Acetylserotonin NT-3 NT-4 Norwogonin (5,7,8-THF) R7 R13 TDP6 TrkC
VEGF Others
Additional growth factors: Adrenomedullin Colony-stimulating factors (see here instead)Connective tissue growth factor (CTGF) Ephrins (A1 , A2 , A3 , A4 , A5 , B1 , B2 , B3 )Erythropoietin (see here instead)Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF) Glia maturation factor (GMF) Hepatoma-derived growth factor (HDGF) Interleukins /T-cell growth factors (see here instead)Leukemia inhibitory factor (LIF) Macrophage-stimulating protein (MSP; HLP, HGFLP) Midkine (NEGF2) Migration-stimulating factor (MSF; PRG4) Oncomodulin Pituitary adenylate cyclase-activating peptide (PACAP) Pleiotrophin Renalase Thrombopoietin (see here instead)Wnt signaling proteins Additional growth factor receptor modulators: Cerebrolysin (neurotrophin mixture)
